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Thirty five of them have acquired risk factors (arterial hypertension, 
dyslipidemia, diabetes mellitus, atrial fibrillation, obstructive sleep 
apnea, smoking, oral contraceptives, family history) and hyperhomo-
cysteinemia. The prevalence of acquired risk factors for stroke are 
significantly higher in ischemic stroke patients without thrombosis 
and clinically significant stenosis.
Conclusions: We found that thrombophilia could be a risk factor for 
thrombosis or severe stenosis in young patients with stroke.
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Background: BCR- ABL tyrosine kinase inhibitors (TKIs) are the main-
stay of the treatment for chronic myeloid leukemia (CML). New gen-
eration TKIs (dasatinib, nilotinib, bosutinib and ponatinib) increase the 
risk of arterial thromboembolism in patients with CML. Clinical data 
suggest that new generation TKIs might accelerate atherogenesis.
Aims: This research aims to determine the effect of BCR- ABL TKIs 
on endothelial cell survival and major functions using an in vitro 
model (i.e. HUVEC).
Methods: Viability was assessed using MTS and LDH assays fol-
lowing standard protocols. Expression of 3 adhesion molecules (i.e. 
ICAM- 1, VCAM- 1 and E- selectin) was quantified by on- cell ELISA 
after 4- hour TNF- α activation. Endothelial cell migration was evalu-
ated by scratch assays (i.e. monitoring of wound closure of a scratch 
on confluent monolayer).
Results: At high concentration, dasatinib, nilotinib and ponatinib 
reduce cell metabolism. Additionally, high- dose ponatinib induces 
necrosis as demonstrated by increased LDH release. On- cell ELISA 
demonstrates decreased expression of 3 adhesion molecules 
(i.e. ICAM- 1, VCAM- 1 and E- selectin) by dasatinib, nilotinib and 
ponatinib at high concentration. This diminution correlates with 
the decreased viability of endothelial cell with these 3 treatments. 
Imatinib and bosutinib have no or little impact on adhesion mol-
ecule expression. Finally, scratch assays indicate that high- dose 
dasatinib inhibits endothelial cell migration whereas other TKIs do 
not have any impact.
Conclusions: Over the 5 commercialized BCR- ABL TKIs, dasatinib, 
nilotinib and ponatinib possess the most impact on endothelial cells 
and possibly promote atherosclerosis development through im-
paired endothelium permeability, enabling migration and trapping of 
lipoprotein into the intima. Determination of mechanism(s) by which 
TKIs promote cardiovascular events is required to implement appro-
priate risk minimization measures and select patients to whom the 
prescription of these drugs should be avoided.
PB498 | Impaired Fibrinolytic Activity in 
Nigerian Myocardial Infarction Patients
O.I. Ajayi; F.S. Ozimede
University of Benin, Physiology, Benin City, Nigeria
Background: Myocardial infarction (MI) is referred to as the changes 
that occur in cardiac muscle and the sudden deprivation of circulat-
ing blood leading to necrosis of myocardial tissue. The pathogen-
esis has been well documented in countries with advanced medical 
technologies while in developing countries such as Nigeria, MI as an 
unfolding major cardiovascular events leading to sudden death in 
most cases.
Aims: This study was designed to ascertain the fibrinolytic patterns 
in acute MI events with a view to indicate their possible role in diag-
nosis and management.
Methods: A total of 10 acute myocardial infarction (AMI) patients 
together with 20 age and sex - matched apparently healthy subjects 
as controls were studied. Blood samples were taken at the point of 
admission (Day 0), on the 4th and 7th day respectively after treat-
ment has commenced. Fibrinolytic indices such D- dimer concentra-
tion (DDC) and Euglobulin lysis time test (ELT) were measured with 
standard laboratory methods.
Results: We observed a significantly increase in Euglobin lysis 
time as well as in increased D- dimer levels AMI patients on admis-
sion compared with controls (P<0.05, respectively). DDC became 
significantly lowered from the 4th day of admission while all the 
ELT remained significantly high until the 7th day of admission and 
treatment (P<0.05, respectively). On the other hand lipids such as 
Cholesterol and HDL remained relatively unchanged from admission 
and throughout the duration of the study.
Conclusions: Conclusively, impaired fibrinolytic activity could be a 
major associated risk of thrombosis in Nigerians with AMI. The role 
of lipids in AMI pathogenesis in Nigerians seem to be unpronounced.
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Background: Fibrin, shear stress and active Factor X (FXa) induce 
glycoprotein (GP) VI shedding independent of direct thrombin ac-
tivity. A Disintegrin And Metalloproteinase (ADAM) 10 is the main 
sheddase releasing human platelet soluble GPVI ectodomain.
Aims: To assess molecular links between these agonists and 
ADAM10 activity.
